Early Detection Research Network


This biomarker is also known as:
  • alpha-methylacyl-CoA racemase,
  • RM,
  • 2-methylacyl-CoA racemase,
  • RACE,
  • CBAS4,
  • AMACR,


AMACR, a racemase, is an enzyme that interconverts pristanoyl-CoA and C27-bile acylCoAs between their (R)- and (S)-stereoisomers. The conversion to the (S)-stereoisomers is necessary for degradation of these substrates by peroxisomal beta-oxidation. Encoded proteins from the gene locus localize to both mitochondria and peroxisomes. Mutations in this gene may be associated with adult-onset sensorimotor neuropathy, pigmentary retinopathy, and adrenomyeloneuropathy due to defects in bile acid synthesis. Frequent overexpression of AMACR has been detected in prostate cancer tumors.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Protein

The following organs have data associated with this biomarker…


Phase: Three
QA State: Curated


AMACR is overexpressed in prostate cancer and may be useful in the interpretation of prostate needle biopsy specimens that are diagnostically challenging.

Performance Comment

Increased AMACR transcript expression can be a predictor of prostate cancer. A multiplexed model including seven biomarkers (AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, TMPRSS2:ERG) outperforms serum PSA or PCA3 alone.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.